Source comparison
KLOW vs TB-500: Research Application Comparison
Primary Mechanism NF-κB pathway inhibition, reducing inflammatory cytokine transcription Actin sequestration and upregulation, promoting cell migration and angiogenesis KLOW suppresses inflammatory signalling; TB-500 accelerates structural repair. Functionally
This comparison does not assign a generated winner or score.
- Primary Mechanism
- NF-κB pathway inhibition, reducing inflammatory cytokine transcription
- Actin sequestration and upregulation, promoting cell migration and angiogenesis
- KLOW suppresses inflammatory signalling; TB-500 accelerates structural repair. Functionally orthogonal pathways
- Ideal Research Application
- Inflammatory bowel conditions, systemic inflammation models, autoimmune dysregulation studies
- Soft tissue injury, tendon repair, post-surgical healing models, cardiac ischemia research
- KLOW targets chronic inflammation without tissue damage; TB-500 targets tissue damage with or without inflammation
- Typical Dosing Protocol
- 500 mcg–2 mg per administration, subcutaneous or oral (context-dependent), daily to twice-daily
- 2–10 mg per administration, subcutaneous injection, administered 2–3 times weekly
- KLOW requires more frequent dosing due to shorter half-life; TB-500 maintains plasma levels longer
- Reconstitution Requirements
- Bacteriostatic water, stable at 2–8°C for 28 days post-reconstitution
- Both are lyophilised peptides requiring identical storage and reconstitution protocols
- Evidence Base
- Phase II clinical data for ulcerative colitis (published 2016); multiple murine inflammation models
- Extensive preclinical data in wound healing, cardiac repair, and tendon regeneration; no FDA-approved human trials
- TB-500 has broader preclinical validation; KLOW has progressed further into human clinical trials for specific indications
- Synergistic Pairing
- Often paired with BPC-157 or other gut-repair peptides in GI inflammation protocols
- Frequently combined with BPC-157 for systemic tissue repair or GHK-Cu for enhanced collagen synthesis
- Both pair well with BPC-157, but for different reasons: KLOW reduces the inflammatory response BPC-157 can't fully address; TB-500 accelerates the structural repair BPC-157 initiates
- The comparison table underscores the fundamental difference: KLOW is a regulatory peptide that modulates immune signalling, while TB-500 is a structural peptide that rebuilds tissue architecture. Researchers selecting between them must first identify whether the primary constraint is inflammatory dysregulation or tissue damage. They're not interchangeable solutions.